Pancreatic cancer is a highly malignant tumor of the digestive system, commonly known as the “king of cancers”. At present, there are no so-called effective drugs that can achieve a clinical cure for pancreatic cancer, and there is no qualitative improvement in survival. The so-called imported effective drugs for pancreatic cancer may be imported chemotherapy drugs, such as gemcitabine, cisplatin, paclitaxel, fluorouracil, etc., or targeted therapy drugs, such as olaparib, erlotinib, everolimus, sunitinib, etc., which have poor overall efficacy. Chemotherapy for pancreatic cancer can be used for pancreatic cancer patients who cannot undergo surgery, and also for the comprehensive treatment of pancreatic cancer after surgery, which can be applied as single drug or in combination; the application can be applied orally or intravenously. Among the so-called targeted drugs, erlotinib is mainly applied to treat patients with locally advanced unresectable or metastatic pancreatic cancer; everolimus and sunitinib are mainly applied to inoperable, progressive neuroendocrine carcinoma tumors. With these drugs, some patients with pancreatic cancer may be able to get some degree of survival time extension.